Bristol Myers Squibb - News
网页2024年9月10日 — Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
FDA approves Bristol Myers Squibb's schizophrenia drug
网页2 天之前 — The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more ...
Bristol Myers Squibb - U.S. Food and Drug Administration …
网页3 天之前 — PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. 1 COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating ...
Absence of Black Box Warning For Bristol Myers' Schizophrenia …
网页1 天前 — On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb …
网页2 天之前 — Bristol Myers Squibb’s revenue has risen just 0.8% from $46.2 billion in 2022 to $46.5 billion in the last twelve months. The revenues can be clubbed under two segments – Legacy Portfolio ...
Bristol-Myers Squibb stock gains on FDA approval of …
网页2 天之前 — Fri, Sep 27, 2024, 8:24 AM 2 min read. Investing.com -- Bristol-Myers Squibb (NYSE:BMY) shares rallied 4.45% in premarket trading Friday following the announcement that the U.S. Food and Drug ...
Bristol Myers Squibb Stock Rises After Schizophrenia
网页2 天之前 — Bristol Myers Squibb said Cobenfy gives patients an important new option to current schizophrenia therapy. Shares of Bristol Myers Squibb (BMY) rose Friday, a day after the Food and Drug ...
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia Drug …
网页2 天之前 — Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions with the serious mental disorder.
Bristol-Myers Squibb’s Cobenfy Launch Spurs ‘Buy’ Rating Amid …
网页2 天之前 — Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical ...
Bristol Myers Squibb (BMY) earnings Q2 2024 - CNBC
网页2024年7月26日 — Bristol Myers Squibb on Friday reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance as the drugmaker moves to slash costs. The pharmaceutical...
跳至内容